B.A

Blue Wolf Capital Names Steve Sleigh Senior Advisor

Retrieved on: 
Martedì, Giugno 11, 2024
Asset Management, Professional Services, Finance, IAM, AMAL, Yucaipa Companies, Labour, City University, City, Research, Retirement, B.A, International Association, Wolf, Senior advisor, Trade, Growth, Sociology, Partner (business rank), Amalgamated Bank, University, Investment, Machinist, ESG, University of Massachusetts, Harvard University, Blue Wolf, Interior design

Blue Wolf Capital Partners LLC (“Blue Wolf”), a middle market private equity firm specializing in the industrial and healthcare sectors, today announced that Steve Sleigh will be a Senior Advisor to the firm.

Key Points: 
  • Blue Wolf Capital Partners LLC (“Blue Wolf”), a middle market private equity firm specializing in the industrial and healthcare sectors, today announced that Steve Sleigh will be a Senior Advisor to the firm.
  • Dr. Sleigh’s new role with Blue Wolf follows the retirement of Mike Musuraca, the firm’s longtime Senior Advisor for ESG and Labor.
  • “Mike has been a trusted colleague and advisor to Blue Wolf since the firm’s founding almost twenty years ago,” said Adam Blumenthal, Chairman and Managing Partner at Blue Wolf.
  • “Over his career, Steve has earned a reputation as a respected leader with deep experience bringing together labor, business, and investors like Blue Wolf to make transformational investments that build great companies and create good jobs,” said Jeremy Kogler, Managing Partner at Blue Wolf.

Veracyte Announces that New Afirma GRID Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors

Retrieved on: 
Lunedì, Giugno 3, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, ENDO, Endocrinology, GSC, Trial of the century, Aggression, Patient, Thyroid, Signature, Cancer, Intelligence, Thyroid cancer, Thyroid nodule, Prostate cancer, Pathology, Metastasis, B.A, Endocrine Society, Risk, Gene expression, FOLH1, Progression-free survival, Fibroblast, Vanderbilt University Medical Center, Correlation, FNA

“Clinicians generally want to avoid overtreatment of patients with non-aggressive thyroid tumors while targeting more-intensive treatment to those patients with aggressive disease.

Key Points: 
  • “Clinicians generally want to avoid overtreatment of patients with non-aggressive thyroid tumors while targeting more-intensive treatment to those patients with aggressive disease.
  • The challenge is distinguishing between them, especially given the heterogeneity of thyroid tumors,” said Joshua Klopper, M.D., Veracyte’s medical director for Endocrinology.
  • “The studies presented at ENDO 2024 today show how our Research-Use-Only Afirma GRID tool, which leverages our whole-transcriptome-derived testing approach, is helping scientists better understand important nuances in the molecular underpinnings of thyroid tumors.
  • Researchers leveraged the Afirma GRID database to characterize the expression of PSMA (FOLH1) in a cohort of nearly 50,000 thyroid nodules sent for Afirma GSC molecular testing.

BARK Bolsters Leadership Team With the Appointment of Meghan Knoll

Retrieved on: 
Giovedì, Maggio 30, 2024
Online Retail, Retail, Other Consumer, Consumer, Other Retail, Specialty, Pets, B.A, DTC, University, Senior, Growth, Direct, Nickelodeon, Dog, Cat Person, Viacom

BARK, Inc. (NYSE: BARK) (“BARK” or the “Company”), a leading global omnichannel dog brand with a mission to make all dogs happy, today announced the appointment of Meghan Knoll as Chief Direct-to-Consumer Officer, effective June 3, 2024.

Key Points: 
  • BARK, Inc. (NYSE: BARK) (“BARK” or the “Company”), a leading global omnichannel dog brand with a mission to make all dogs happy, today announced the appointment of Meghan Knoll as Chief Direct-to-Consumer Officer, effective June 3, 2024.
  • Reporting to the Company’s Co-Founder and Chief Executive Officer, Matt Meeker, Ms. Knoll will lead BARK’s direct-to-consumer (“DTC”) business.
  • “On behalf of the entire team, I am thrilled to welcome Meghan Knoll back to BARK.
  • The team has made impressive progress within the direct-to-consumer channel in the past 18 months,” said Meghan.

Nurix Therapeutics Appoints Paula G. O’Connor, M.D., as Chief Medical Officer and Pasit Phiasivongsa, Ph.D., as Chief Technical Officer

Retrieved on: 
Martedì, Maggio 28, 2024
Patient, Yale University, Medivation, Genentech, Chronic lymphocytic leukemia, Biochemistry, Patent, Stanford University, B.A, University, Pacific Ocean, Therapy, Dana–Farber Cancer Institute, Head, Drug development, SAN, AIDS, Inflammation, Cancer, CMC, Drug discovery, Hematology, Psychology, Pharmaceutical industry

She trained as a hematologist-oncologist and has more than 15 years of drug development expertise.

Key Points: 
  • She trained as a hematologist-oncologist and has more than 15 years of drug development expertise.
  • Prior to joining Nurix, Dr. O’Connor held senior level positions in clinical development and medical affairs at Protagonist Therapeutics, Oncopeptides, Inc., Coherus Biosciences, Medivation, Onyx, and Genentech.
  • Dr. Phiasivongsa joined Nurix in August 2022 and most recently served as executive vice president of technical operations.
  • Before Kronos, Dr. Phiasivongsa served in senior CMC leadership roles at Principia Biopharma and Tobira Therapeutics.

Actio Biosciences Appoints Ben Cravatt, Ph.D., to Board of Directors

Retrieved on: 
Mercoledì, Maggio 22, 2024
Research, Genetics, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Scripps Research, American Academy, Faculty, Biology, Royal, Bayer, Education, Heart, Stanford University, B.A, Searle, Therapy, Disease, Physiology, Biochemistry, National academy, Chemical biology, National Academy of Medicine, Searle Scholars Program, Drug discovery, Gene, TSRI, Medicine, Wolf Prize in Chemistry, Royal Society, History, Wolf Prize, Scripps, Pharmaceutical industry

Actio Biosciences, a biotechnology company leveraging a novel platform approach to genetics and precision medicine to develop new therapeutics that target shared underlying biology in both rare and common diseases, today announced that Ben Cravatt, Ph.D., has joined the company’s board of directors.

Key Points: 
  • Actio Biosciences, a biotechnology company leveraging a novel platform approach to genetics and precision medicine to develop new therapeutics that target shared underlying biology in both rare and common diseases, today announced that Ben Cravatt, Ph.D., has joined the company’s board of directors.
  • Dr. Cravatt is professor and Norton B. Gilula Chair of Chemical Biology in the Department of Chemistry at The Scripps Research Institute.
  • “By combining genuine expertise across biology, chemistry and genetics, Ben has pioneered an approach to drug discovery and development that sits at the heart of Actio’s mission,” said David Goldstein, Ph.D., co-founder and CEO of Actio.
  • He received a Ph.D. from The Scripps Research Institute (TSRI) in 1996 and joined the faculty at TSRI in 1997.

Cranfill Sumner Launches MBM in Washington, D.C., with Partners Patrick Mincey and Stephen Bell and Christina Zaroulis Milnor, Former Assistant Secretary of the SEC

Retrieved on: 
Mercoledì, Maggio 1, 2024
Consulting, Professional Services, Legal, United Nations, University, General counsel, Truth Social, Financial Crimes Enforcement Network, Social media, Lawyer, Comptroller, Kremlin, Vladimir Putin, Security (finance), False Claims Act, Intelligence, B.A, MBM, DOJ, Bell, Multimedia, Assistant, Currency, Government, Harvard University, PDVSA

The new group, Mincey Bell Milnor (MBM) will focus on white collar, regulatory enforcement, high-stakes civil litigation, and representation of whistleblowers before federal agencies.

Key Points: 
  • The new group, Mincey Bell Milnor (MBM) will focus on white collar, regulatory enforcement, high-stakes civil litigation, and representation of whistleblowers before federal agencies.
  • “With MBM, we have landed a prominent government official, just exiting the SEC, paired with two nationally known white collar litigators.
  • We set it up this way so these lawyers could have the visibility of a boutique group with the platform of our larger firm.
  • We plan to continue to grow the practice from here.”
    Milnor has held significant roles at the SEC for more than a decade.

Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer

Retrieved on: 
Martedì, Aprile 30, 2024
Professional Services, Health, Infectious Diseases, Legal, Clinical Trials, Pharmaceutical, Biotechnology, Corporation, University, General counsel, Eli Lilly, ARIAD Pharmaceuticals, Virology, Hall, Civil Service (United Kingdom), B.A, Patient, Acquisition, White, Caregiver, Proteon Therapeutics, Multimedia, Intellectual property, Notre Dame Law School, Medication, Therapy, Cubist Pharmaceuticals, Growth, Pharmaceutical industry

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the appointment of Matthew P. Kowalsky, J.D., as Chief Legal Officer.

Key Points: 
  • Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the appointment of Matthew P. Kowalsky, J.D., as Chief Legal Officer.
  • In this role, he will lead all legal and compliance activities for Enanta, as well as provide strategic guidance and corporate governance oversight.
  • Prior to joining Enanta, Mr. Kowalsky held legal and operational roles of increasing responsibility at Sigilon Therapeutics, Inc., until its acquisition by Eli Lilly in 2023.
  • Most recently, he served as the Chief of Staff and Chief Legal and Administrative Officer of Sigilon, which he joined in 2019 as its General Counsel and Corporate Secretary.

Great Eagle Gold Corp. Welcomes Gene McBurney as Strategic Advisor and Announces Board and Management Reorganization

Retrieved on: 
Venerdì, Aprile 5, 2024
ECM, Growth, CFO, M.A, Natural Resources, International, Accounting, Gold, Gene, History, Acquisition, LL.B, Mining, McBurney, B.A, Legislation, Corporation

McBurney has a notable history of leading landmark transactions in natural resources, demonstrating his capability to deliver strategic outcomes for his clients.

Key Points: 
  • McBurney has a notable history of leading landmark transactions in natural resources, demonstrating his capability to deliver strategic outcomes for his clients.
  • Additionally, Gene has extensive investment banking experience throughout the Caribbean and Latin America, with a special emphasis on Colombia.
  • Great Eagle Gold is pleased to announce Gary Harbottle as the new CFO, while also expressing gratitude to Martin Bajic for his dedicated service.
  • Great Eagle also regrets to announce the resignation of Kate Fehlenberg from the Board of Directors, but she will continue to provide advisory and consulting services to Great Eagle.

The Cannabis Business Museum Opens Inaugural Call for Submissions

Retrieved on: 
Mercoledì, Marzo 20, 2024
Federation, University, B.A, Government, Drug

Archiving milestones of the global legal recreational cannabis industry

Key Points: 
  • Toronto, Ontario--(Newsfile Corp. - March 20, 2024) - The inaugural call for submissions by the Cannabis Business Museum is now open.
  • Submit images of content and memorabilia from early days of recreational cannabis legalization by accessing the form on The Cannabis Museum Website .
  • The call is open to all members of the public to present archival content on recreational legal cannabis.
  • The museum will collect a decade of material accessible on the website by 2025- highlighting the significant milestones, brands, and leaders that paved the way for modern cannabis products.

Making Long-Term Memories Requires Nerve-Cell Damage

Retrieved on: 
Mercoledì, Marzo 27, 2024
Inflammation, Radulović, Psychiatry, Brain, TLR9, COVID, Gene, DNA repair, DSM-IV codes, Cell division, Genome instability, University Medical Center, Infection, Memory, Organelle, Hippocampus, Mouse, DNA, Albert Einstein, Nature, Cancer, Toll-like receptor 9, Neuron, Northwestern University, Doctor of Philosophy, Alzheimer's disease, Genome, Aarhus University, Cytoplasm, Cell, Dominic, B.A, Encephalitis, Ageing, Vaccine

"But our findings suggest that inflammation in certain neurons in the brain's hippocampal region is essential for making long-lasting memories."

Key Points: 
  • "But our findings suggest that inflammation in certain neurons in the brain's hippocampal region is essential for making long-lasting memories."
  • But looking more closely, we found, to our surprise, that TLR9 was activated only in clusters of hippocampal cells that showed DNA damage."
  • But in this population of hippocampal neurons, the DNA damage appeared to be more substantial and sustained.
  • Importantly, the researchers found that blocking the TLR9 inflammatory pathway in hippocampal neurons not only prevented mice from forming long-term memories but also caused profound genomic instability, i.e, a high frequency of DNA damage in these neurons.